It has been recently shown that the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib triggered a massive apoptotic response only in BRAFV600E CRC cells harboring also TERT promoter mutations but not in BRAFV600E cells lacking TERT mutations. This evidence concerns the gene BRAF and colorectal carcinoma.